News

Patients with autoimmune hepatitis who are deficient in vitamin D had worse outcomes than patients with normal vitamin D levels.

Stine reviews findings from a posthoc analysis of the NASHFit trial suggesting the impact of exercise on MASH resolution, even without weight loss.

Reducing systolic blood pressure to less than 120 mmHg lowered the risk of major cardiovascular events for most people with diabetes in the BPROAD trial.

Tirzepatide reduced the risk of heart failure hospitalization or cardiovascular death by 38% and improved body weight by up to 21% in the SUMMIT trial.

Zoi Papalamprakopoulou, MD, explains telehealth’s potential to aid HCV treatment in high-risk populations and how patients perceive this care modality.

In this cross-sectional survey analysis, new insights were explored regarding clinical practice patterns and treatment outcomes within dermatology practices in the US.

Zhang describes how a novel multidisciplinary care clinic has helped reduce relapse after transplant in patients with alcohol-associated liver disease.

Once-daily aprocitentan is indicated to help lower blood pressure in adult patients with hypertension who are inadequately controlled on other medications.

New phase 2b data suggest a combination of VTP-300 and low-dose nivolumab can stimulate immune response and induce HBV functional cure.

Findings from a 2.5-year interim analysis from the ongoing phase 3 ASSURE study highlight seladelpar’s sustained efficacy and long-term safety for PBC.

The announcement of the resubmission by Regeneron and Sanofi follows LIBERTY-CUPID phase 3 clinical findings on dupilumab for patients with CSU.

In this analysis in Thailand, video education’s impact on patient guardians’ knowledge was assessed with the aim of reducing eczema severity.

In this analysis, the benefits of 2’-FL for mothers’ offspring with regard to allergies were highlighted by investigators.

At NASPGHAN, HCPLive spoke with Margolis about her team’s study on the link between maternal SSRI exposure and an infant’s development of gut-brain interaction disorders.

In this episode, hosts explore the most recent updates surrounding GLP-1 receptor agonists, including GLP-1 shortages and long-term data on tirzepatide.

A study found a 3.5-fold increased schizophrenia risk in those with hallucinogen-related emergency department visits.

In areas where HBV immune globulin is not available, maternal TDF therapy at week 16 and infant HBV vaccination can prevent mother-to-child transmission.

Laura Ross, PA-C, shares insights from the inaugural CAPP meeting on how lifestyle medicine and targeted therapies are transforming cardiovascular care.

A study presented at NASPGHAN 2024 reveals rising incidence rates and improved survival outcomes of Biliary Atresia in the US.

In this episode, hosts discuss the latest developments in GLP-1 receptor agonists, with a particular focus on semaglutide.

A new analysis highlights the seasonal patterns of airborne fungal spores that can be found in the central region of England, with a calendar developed to this same end.

Past APAC President Viet Le shares insights from CAPP 2024 on managing high-risk ASCVD, new non-statin therapies, and options for statin-intolerant patients.

These data on patients with hidradenitis suppurativa point to several factors as being associated with diagnostic wandering.

The acceptance of the investigational gene therapy’s Biologics License Application was announced, with the treatment designed for recessive dystrophic epidermolysis bullosa.

Maternal SSRI use was linked to a higher risk of constipation in infants, while untreated maternal depression was tied to colic. Margolis discussed these findings at NASPGHAN.

Initiation of population-wide CKD screening followed by conventional CKD treatment plus SGLT2 inhibitors at 55 years of age was cost-effective.

In this latest episode of Lungcast, multiple points of view are highlighted regarding Aspirin-Exacerbated Respiratory Disease (AERD).

The risk score uses routine clinical data to assess hepatocellular carcinoma risk in patients without viral hepatitis or hepatic decompensation.